Evan Schwartz, CEO of Aloe Care Health
America is about to experience the most expensive decade in the history of healthcare. Within five years, one in five Americans will be 65 or older. By 2034,…
Continue Reading
Lucienne Ide, MD, PhD, Founder and CEO of Rimidi
The annual release of the Medicare Physician Fee Schedule (PFS) generated more attention than usual this year among practices that have considered or are already offering…
Continue Reading
Overview of 2026 Payment Increases
The Centers for Medicare and Medicaid Services (CMS) released its final physician fee schedule for 2026 on Friday night, marking a significant milestone for healthcare providers across the nation. The…
What You Should Know:
– The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule for the Calendar Year (CY) 2026 Medicare Physician Fee Schedule (PFS).
– The proposal aims to increase quality…
Continue Reading
What You Should Know:
– The newly published AMGA 2025 Medical Group Compensation and Productivity Survey reveals substantial increases in compensation for various clinical specialties in 2024. The comprehensive analysis, encompassing data from over 184,000…
Continue Reading
Lucienne Marie Ide, M.D., PH.D., Founder and Chief Executive Officer of RimidI
The care management code updates in the 2025 Final Physician Fee Schedule from Centers for Medicare & Medicaid Services (CMS) could have far-reaching…
Continue Reading
Lucienne Ide, MD, PhD, Founder and CEO of Rimidi
The Centers for Medicare and Medicaid Services (CMS) update to the 2025 Physician Fee Schedule includes a measure that holds significant promise for advancing cardiovascular disease…
Continue Reading
The American Telemedicine Association and ATA Action in a letter to the Centers for Medicare and Medicaid Services seeks to preserve pandemic-era Medicare telehealth flexibilities that it says are responsible for improving access to…
Continue Reading
Digital therapeutics have significantly improved access to care for many patients, while delivering consistent clinical outcomes across a wide range of conditions. However, despite the potential these new treatments offer, convincing payers to embrace…
Continue Reading
When the FDA approves a drug, passing that regulatory bar of safety and efficacy puts it on the path toward likely reimbursement by government and commercial payers. The same has not been true for…
Continue Reading
